Many studies have recognized LEAP-2 as a potential therapeutic target for ghrelin-related diseases, including obesity, cachexia, diabetes, anorexia, alcohol abuse, and Prader–Willi syndrome [8,18]. Here, LEAP2 is linked to obesity due to melanocortin 4 receptor deficiency.